Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 1.0
Zymeworks Inc. amended Amended and Restated License and Collaboration Agreement with Jazz Pharmaceuticals Ireland Limited valued at Amendment to transfer responsibility for the Program to Jazz, with unchanged financial terms except (effective 2023-05-15).
- Action
- amendment
- Agreement
- collaboration
- Counterparty
- Jazz Pharmaceuticals Ireland Limited
- Value
- Amendment to transfer responsibility for the Program to Jazz, with unchanged financial terms except
- Effective
- 2023-05-15
Exact text from the filing
Amended Jazz Collaboration Agreement As previously disclosed, on October 18, 2022, Zymeworks BC Inc. (“Zymeworks BC”), a subsidiary of Zymeworks Inc. (the “Company”), entered into a License and Collaboration Agreement (the “Original Jazz Collaboration Agreement”) with Jazz Pharmaceuticals Ireland Limited (a subsidiary of Jazz Pharmaceuticals plc, collectively referred to as “Jazz”), an affiliate of Jazz Pharmaceuticals, Inc. (“Jazz Inc.”), granting Jazz exclusive rights to develop and commercialize Zymeworks BC’s proprietary bispecific HER2 antibody product candidate known as zanidatamab throughout the world, but excluding existing Asia Pacific territories (other than Japan) already governed by Zymeworks BC’s agreement with BeiGene, Ltd. (the “Territory”). As previously disclosed, as part of the Transactions contemplated by the Transfer Agreement (as these terms are defined below), on May 15, 2023, Zymeworks BC and Jazz entered into an Amended and Restated License and Collaboration Agr
View on SEC.gov